Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
Age
1–11
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with stable CF and at least 1 TCR mutation (including F508del) in the CFTR gene
You may not be if
History of solid organ, hematological transplantation, or cancer
Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)
Lung infection with organisms associated with a more rapid decline in pulmonary status
Clareo Health | Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
